References
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41
- Lane NE, Sanchez S, Genant HK, et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000;11:434–42
- Chen P, Satterwhite J, Licata AA, et al. Early changes in biochemical markers of bone formation predict bone mineral density response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962–70
- Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117–23
- Delmas PD, Vrijens B, Roux C, et al. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res 2003;18:S374
- Hannon R, Blumsohn A, Naylor K, et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124–33
- Braga de Castro MA, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14:602–8
- Efron B, Stein C. The jackknife estimate of variance. Ann Stat 1981;9:586–96
- McClung M, San Martin J, Miller PD, et al. Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005;165(15):1762–68
- Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745–51
- Blumsohn A, Brixen K, Sigurdsson G, et al. Early change in bone turnover following teriparatide (RhPTH1–34) In the Eurofors Study: influence of prior therapy and association with BMD change at one year. J Bone Miner Res 2005; 20(Suppl 1):S411
- Clowes JA, Peel NF, Hannon RA, et al Relative utility of new serum markers of bone turnover for monitoring raloxifene therapy. J Bone Miner Res 2003;18\(Suppl 2):SU373
- Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344–51
- Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886–90
- Chen P, Miller PD, Delmas PD, et al. Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res 2005; 20(Suppl 1): S175
- Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566–75
- Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207–15
- Finkelstein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618–23
- Ste-Marie LG, Schwartz SL, Hossain AM, et al. Effect of teriparatide [rh parathyroid hormone (1–34)] on bone density when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2005 (in press)
- Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Min Res 2005;20:1905–11
- Lomeo A, Bolner A. Stability of several biochemical markers of bone metabolism. Clin Chem 2000;46(8):1200–02